secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001785530-23-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q3 net loss $8.3M; WTX-124 shows early antitumor activity
-------------------------------------------------------------------------------

- Cash $130.1M as of Sep 30; sufficient to fund operations through Q4 2024.
- Collaboration revenue $5.9M (vs $5.0M prior year); net loss $8.3M (vs $11.9M).
- WTX-124 Phase 1 data: well-tolerated, two unconfirmed partial responses at 12 mg, no Grade 3+ related AEs.
- WTX-330 dose escalation ongoing; WTX-124 expansion expected to open in H1 2024.
- New pipeline candidate WTX-518 (IL-18 INDUKINE) added; preclinical data in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/0001785530-23-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/howl-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001785530-23-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer